ClinConnect ClinConnect Logo
Search / Trial NCT03632083

A Range of Contact Lenses and Care System Combinations

Launched by COOPERVISION, INC. · Aug 13, 2018

Trial Information

Current as of May 18, 2025

Completed

Keywords

ClinConnect Summary

Subjects were randomized to wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Hy-Care contact lens solution and Lite contact lens solution.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. They are of legal age (18) and capacity to volunteer.
  • 2. They understand their rights as a research subject and are willing and able to sign a Statement of Informed Consent.
  • 3. They are willing and able to follow the protocol.
  • 4. They agree not to participate in other clinical research for the duration of this study.
  • 5. They can be satisfactorily fitted with the study lens for a period of approximately 2 hours.
  • 6. They can attain at least 0.20 logMAR distance high contrast visual acuity in each eye with their habitual spectacles.
  • 7. They currently wear daily disposable soft contact lenses or have done so in the previous six months.
  • 8. They are willing to comply with the wear schedule (approximately 2 hours on two different days)
  • 9. They own a wearable pair of spectacles and agree to bring these to study visits.
  • Exclusion Criteria:
  • 1. They have an ocular disorder which would normally contra-indicate contact lens wear.
  • 2. They have a systemic disorder which would normally contra-indicate contact lens wear.
  • 3. They currently wear reusable soft contact lenses in both eyes.
  • 4. They are using any topical medication such as eye drops or ointment.
  • 5. They have had cataract surgery.
  • 6. They have had corneal refractive surgery.
  • 7. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.
  • 8. They are pregnant or breast-feeding.
  • 9. They have any ocular abnormality which would, in the opinion of the investigator, normally contraindicate contact lens wear.
  • 10. They have Type 2 or greater corneal staining prior to lens application at Visit 1 or 2
  • 11. They have corneal staining covering greater than 20% in any corneal region at Visit 1a or 2a
  • 12. They have any infectious disease which would, in the opinion of the investigator, contraindicate contact lens wear or pose a risk to study personnel; or they have any immunosuppressive disease (e.g. HIV), or a history of anaphylaxis or severe allergic reaction.
  • 13. They have taken part in any other contact lens or care solution clinical trial or research, within two weeks prior to starting this study.

About Coopervision, Inc.

CooperVision, Inc. is a global leader in the contact lens industry, dedicated to advancing the science of vision care through innovative products and clinical research. With a commitment to enhancing the quality of life for millions of wearers worldwide, the company specializes in developing a diverse range of contact lenses, including those for myopia control, astigmatism, and presbyopia. CooperVision actively engages in clinical trials to ensure the safety, efficacy, and comfort of its products, while also contributing to the broader understanding of eye health and vision correction. By fostering partnerships with healthcare professionals and researchers, CooperVision aims to drive advancements in vision care and provide exceptional solutions that meet the evolving needs of eye care practitioners and their patients.

Locations

Manchester, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Philip Morgan, PhD MCOptom FAAO FBCLA

Principal Investigator

Eurolens Research

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials